Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-04-17 @ 7:20 AM
Study NCT ID:
NCT01761266
Status:
COMPLETED
Last Update Posted:
2022-04-05
First Post:
2013-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}, {'id': 'D009369', 'term': 'Neoplasms'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C531958', 'term': 'lenvatinib'}, {'id': 'D000077157', 'term': 'Sorafenib'}], 'ancestors': [{'id': 'D010671', 'term': 'Phenylurea Compounds'}, {'id': 'D014508', 'term': 'Urea'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009536', 'term': 'Niacinamide'}, {'id': 'D009539', 'term': 'Nicotinic Acids'}, {'id': 'D000147', 'term': 'Acids, Heterocyclic'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'esi_oncmedinfo@eisai.com', 'phone': '1-888-274-2378', 'title': 'Eisai Medical Information', 'organization': 'Eisai Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'All treatment-emergent adverse events were collected from first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 8 years)', 'description': 'The safety analysis set included all participants who received at least 1 dose of study drug. All-cause mortality was reported for all participants randomized.', 'eventGroups': [{'id': 'EG000', 'title': 'Lenvatinib', 'description': "Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.", 'otherNumAtRisk': 476, 'deathsNumAtRisk': 478, 'otherNumAffected': 469, 'seriousNumAtRisk': 476, 'deathsNumAffected': 415, 'seriousNumAffected': 209}, {'id': 'EG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.', 'otherNumAtRisk': 475, 'deathsNumAtRisk': 476, 'otherNumAffected': 469, 'seriousNumAtRisk': 475, 'deathsNumAffected': 402, 'seriousNumAffected': 149}], 'otherEvents': [{'term': 'Ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 82, 'numAffected': 63}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 54, 'numAffected': 39}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 95, 'numAffected': 76}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 62, 'numAffected': 52}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 406, 'numAffected': 186}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 448, 'numAffected': 223}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 40, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 20, 'numAffected': 18}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 131, 'numAffected': 90}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 94, 'numAffected': 71}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 67, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 76, 'numAffected': 56}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 110, 'numAffected': 75}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 65, 'numAffected': 37}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 86, 'numAffected': 53}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 108, 'numAffected': 51}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 128, 'numAffected': 64}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 173, 'numAffected': 80}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 59, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 40, 'numAffected': 29}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 141, 'numAffected': 67}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 128, 'numAffected': 63}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Electrocardiogram QT prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 59, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 62, 'numAffected': 24}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 60, 'numAffected': 37}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 41, 'numAffected': 27}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 101, 'numAffected': 41}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 21, 'numAffected': 13}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 260, 'numAffected': 87}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 127, 'numAffected': 59}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 290, 'numAffected': 149}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 182, 'numAffected': 108}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 115, 'numAffected': 47}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 55, 'numAffected': 25}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 269, 'numAffected': 162}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 165, 'numAffected': 126}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypoalbuminaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 88, 'numAffected': 43}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 56, 'numAffected': 38}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 52, 'numAffected': 42}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 31, 'numAffected': 20}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 55, 'numAffected': 48}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 30, 'numAffected': 28}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 56, 'numAffected': 47}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 30, 'numAffected': 25}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 59, 'numAffected': 38}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 32, 'numAffected': 18}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 57, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 48, 'numAffected': 39}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 38, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 34, 'numAffected': 28}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 363, 'numAffected': 117}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 125, 'numAffected': 55}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 54, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 46, 'numAffected': 37}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dysphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 134, 'numAffected': 113}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 69, 'numAffected': 57}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 35, 'numAffected': 35}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 17, 'numAffected': 15}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 41, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 46, 'numAffected': 35}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 59, 'numAffected': 46}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 105, 'numAffected': 77}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 419, 'numAffected': 200}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 269, 'numAffected': 147}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 55, 'numAffected': 35}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 104, 'numAffected': 43}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 81, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 90, 'numAffected': 28}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 104, 'numAffected': 81}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 57, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 27, 'numAffected': 24}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 136, 'numAffected': 82}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 111, 'numAffected': 83}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 82, 'numAffected': 58}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 59, 'numAffected': 41}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 122, 'numAffected': 53}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 84, 'numAffected': 48}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 226, 'numAffected': 141}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 170, 'numAffected': 120}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 107, 'numAffected': 67}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 45, 'numAffected': 33}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 79, 'numAffected': 63}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 74, 'numAffected': 61}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 16, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 140, 'numAffected': 120}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Palmar-plantar erythrodysaesthesia syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 236, 'numAffected': 128}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 614, 'numAffected': 246}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 38, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 33, 'numAffected': 29}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 22, 'numAffected': 16}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 39, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 19, 'numAffected': 17}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 14, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 52, 'numAffected': 26}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 37, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 34, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 11, 'numAffected': 9}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 26, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 33, 'numAffected': 25}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}], 'seriousEvents': [{'term': 'Disseminated intravascular coagulation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Anaemia vitamin B12 deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cardiopulmonary failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Atrial flutter', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Heart valve stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypoacusis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 15, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 15, 'numAffected': 12}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Oesophageal varices haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 7, 'numAffected': 5}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Upper gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 5, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Duodenal ulcer haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 8, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Duodenal ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastric ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Umbilical hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastric haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Intestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pancreatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Varices oesophageal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Enterocolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastric perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastric ulcer haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lower gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Peritoneal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Jaundice cholestatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Portal vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cholangitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 6, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic cirrhosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bile duct obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 7, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bile duct stone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Acute hepatic failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Biliary dilatation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cholecystitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Chronic hepatic failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haemobilia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic function abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatorenal syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hydrocholecystis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Jaundice', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Liver injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 7, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Liver abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lung infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Appendiceal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Biliary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dengue fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Escherichia sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Gastrointestinal viral infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Groin abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Infectious pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lung abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Perihepatic abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Periodontitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pleural infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Postoperative abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pulmonary tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Scrotal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Urinary tract infection enterococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Urosepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Acute sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Aspergillus infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Device related infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diabetic foot infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Ophthalmic herpes simplex', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Perineal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumonia escherichia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Intentional overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Spinal compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Thoracic vertebral fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Foreign body', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Spinal fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Subarachnoid haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Traumatic haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Blood pressure decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Clostridium test positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic enzyme increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haemoglobin decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 5, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 12, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cachexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypercalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypoalbuminaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypocalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypoproteinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pathological fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bone pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Flank pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lumbar spinal stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Rhabdomyolysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Spinal column stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Spinal osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Malignant neoplasm progression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 12, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 14, 'numAffected': 14}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tumour haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Liver carcinoma ruptured', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Metastases to central nervous system', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Metastases to spine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Infected neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Intracranial tumour haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Meningioma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Metastases to bone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Renal cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tumour necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tumour pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tumour rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Lung neoplasm malignant', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Malignant ascites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Malignant pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Plasma cell myeloma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 35, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cerebral haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Coma hepatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cerebral infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Spinal cord compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Diplegia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Disturbance in attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Facial paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Paralysis recurrent laryngeal nerve', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Posterior reversible encephalopathy syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Basal ganglia haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Ischaemic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Thrombotic cerebral infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Major depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Renal failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Renal impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'IgA nephropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Renal tubular necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pelvic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumonia aspiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatopulmonary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Acute respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hiccups', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Necrotising bronchiolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Non-cardiogenic pulmonary oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pulmonary infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Intertrigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Seborrhoeic dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Drug eruption', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Erythema multiforme', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Palmar-plantar erythrodysaesthesia syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Aortic dissection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Circulatory collapse', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Thrombophlebitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Thrombophlebitis superficial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 12, 'numAffected': 6}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Bone marrow failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'General physical health deterioration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Multiple organ dysfunction syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Generalised oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Organ failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Peripheral swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Sudden death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Hepatic failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 22, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 11, 'numAffected': 8}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 11, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Peritonitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Salmonellosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Accidental overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pneumothorax traumatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cancer pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Confusional state', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Suicide attempt', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Mantle cell lymphoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Metastases to adrenals', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 476, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 475, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.6', 'spread': '12.1', 'groupId': 'OG000', 'lowerLimit': '12.1', 'upperLimit': '14.9'}, {'value': '12.3', 'spread': '10.4', 'groupId': 'OG001', 'lowerLimit': '10.4', 'upperLimit': '13.9'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From date of randomization until date of death from any cause (approximately up to 3.8 years)', 'description': 'OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Progression Free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.4', 'spread': '6.9', 'groupId': 'OG000', 'lowerLimit': '6.9', 'upperLimit': '8.8'}, {'value': '3.7', 'spread': '3.6', 'groupId': 'OG001', 'lowerLimit': '3.6', 'upperLimit': '4.6'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Time to Progression (TTP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.9', 'spread': '7.4', 'groupId': 'OG000', 'lowerLimit': '7.4', 'upperLimit': '9.2'}, {'value': '3.7', 'spread': '3.6', 'groupId': 'OG001', 'lowerLimit': '3.6', 'upperLimit': '5.4'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)', 'description': 'TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Objective Response Rate (ORR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '24.1', 'spread': '20.2', 'groupId': 'OG000', 'lowerLimit': '20.2', 'upperLimit': '27.9'}, {'value': '9.2', 'spread': '6.6', 'groupId': 'OG001', 'lowerLimit': '6.6', 'upperLimit': '11.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.7', 'spread': '1.05', 'groupId': 'OG000', 'lowerLimit': '1.05', 'upperLimit': '1.84'}, {'value': '1.8', 'spread': '1.05', 'groupId': 'OG001', 'lowerLimit': '1.05', 'upperLimit': '1.84'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'title': 'Fatigue', 'categories': [{'measurements': [{'value': '1.9', 'spread': '1.81', 'groupId': 'OG000', 'lowerLimit': '1.81', 'upperLimit': '1.97'}, {'value': '1.8', 'spread': '1.74', 'groupId': 'OG001', 'lowerLimit': '1.74', 'upperLimit': '1.87'}]}]}, {'title': 'Jaundice', 'categories': [{'measurements': [{'value': '4.6', 'spread': '3.72', 'groupId': 'OG000', 'lowerLimit': '3.72', 'upperLimit': '5.52'}, {'value': '3.7', 'spread': '2.86', 'groupId': 'OG001', 'lowerLimit': '2.86', 'upperLimit': '4.73'}]}]}, {'title': 'Body Image', 'categories': [{'measurements': [{'value': '2.8', 'spread': '2.73', 'groupId': 'OG000', 'lowerLimit': '2.73', 'upperLimit': '3.68'}, {'value': '1.9', 'spread': '1.84', 'groupId': 'OG001', 'lowerLimit': '1.84', 'upperLimit': '2.73'}]}]}, {'title': 'Nutrition', 'categories': [{'measurements': [{'value': '4.1', 'spread': '3.68', 'groupId': 'OG000', 'lowerLimit': '3.68', 'upperLimit': '5.52'}, {'value': '2.8', 'spread': '2.04', 'groupId': 'OG001', 'lowerLimit': '2.04', 'upperLimit': '3.06'}]}]}, {'title': 'Pain', 'categories': [{'measurements': [{'value': '2.7', 'spread': '1.97', 'groupId': 'OG000', 'lowerLimit': '1.97', 'upperLimit': '2.83'}, {'value': '2.8', 'spread': '2.73', 'groupId': 'OG001', 'lowerLimit': '2.73', 'upperLimit': '3.72'}]}]}, {'title': 'Fever', 'categories': [{'measurements': [{'value': '5.5', 'spread': '4.57', 'groupId': 'OG000', 'lowerLimit': '4.57', 'upperLimit': '6.51'}, {'value': '3.7', 'spread': '2.99', 'groupId': 'OG001', 'lowerLimit': '2.99', 'upperLimit': '5.52'}]}]}, {'title': 'Sex Life', 'categories': [{'measurements': [{'value': '7.4', 'spread': '5.46', 'groupId': 'OG000', 'lowerLimit': '5.46', 'upperLimit': '9.17'}, {'value': '6.7', 'spread': '4.60', 'groupId': 'OG001', 'lowerLimit': '4.60', 'upperLimit': '13.78'}]}]}, {'title': 'Abdominal swelling', 'categories': [{'measurements': [{'value': '7.4', 'spread': '5.52', 'groupId': 'OG000', 'lowerLimit': '5.52', 'upperLimit': '9.24'}, {'value': '7.4', 'spread': '5.46', 'groupId': 'OG001', 'lowerLimit': '5.46', 'upperLimit': '10.13'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'title': 'VAS', 'categories': [{'measurements': [{'value': '2.8', 'spread': '2.17', 'groupId': 'OG000', 'lowerLimit': '2.17', 'upperLimit': '3.65'}, {'value': '1.9', 'spread': '1.84', 'groupId': 'OG001', 'lowerLimit': '1.84', 'upperLimit': '2.33'}]}]}, {'title': 'HUI', 'categories': [{'measurements': [{'value': '2.8', 'spread': '1.97', 'groupId': 'OG000', 'lowerLimit': '1.97', 'upperLimit': '3.52'}, {'value': '1.9', 'spread': '1.84', 'groupId': 'OG001', 'lowerLimit': '1.84', 'upperLimit': '2.66'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '150', 'groupId': 'OG000'}, {'value': '318', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib 8 mg', 'description': "Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Lenvatinib 12 mg', 'description': "Participants received lenvatinib 12 mg capsules based on the participant's body weight (\\>=60 kg) at Baseline, orally, once daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}], 'classes': [{'categories': [{'measurements': [{'value': '1969.6', 'spread': '743.0', 'groupId': 'OG000'}, {'value': '2120.9', 'spread': '685.6', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)', 'description': 'AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'nanogram*hour per milliliter (ng*h/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The pharmacokinetic (PK) analysis set included all participants who had received at least 1 dose of lenvatinib and had at least 1 quantifiable lenvatinib concentration.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Disease Control Rate (DCR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '75.5', 'spread': '71.7', 'groupId': 'OG000', 'lowerLimit': '71.7', 'upperLimit': '79.4'}, {'value': '60.5', 'spread': '56.1', 'groupId': 'OG001', 'lowerLimit': '56.1', 'upperLimit': '64.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \\>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Clinical Benefit Rate (CBR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'OG000'}, {'value': '476', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'categories': [{'measurements': [{'value': '59.0', 'spread': '54.6', 'groupId': 'OG000', 'lowerLimit': '54.6', 'upperLimit': '63.4'}, {'value': '38.4', 'spread': '34.1', 'groupId': 'OG001', 'lowerLimit': '34.1', 'upperLimit': '42.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \\>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were randomized.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Percent Change From Baseline in Serum Biomarker', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Lenvatinib', 'description': "Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'OG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'classes': [{'title': 'ANG 2: Cycle 1 Day 15', 'categories': [{'measurements': [{'value': '-28.1', 'spread': '15.94', 'groupId': 'OG000', 'lowerLimit': '15.94'}, {'value': '8.9', 'spread': '23.96', 'groupId': 'OG001', 'lowerLimit': '23.96'}]}]}, {'title': 'ANG 2: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '-28.8', 'spread': '16.53', 'groupId': 'OG000', 'lowerLimit': '16.53'}, {'value': '-0.9', 'spread': '24.06', 'groupId': 'OG001', 'lowerLimit': '24.06'}]}]}, {'title': 'ANG 2: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '-32.2', 'spread': '23.23', 'groupId': 'OG000', 'lowerLimit': '23.23'}, {'value': '0.5', 'spread': '26.62', 'groupId': 'OG001', 'lowerLimit': '26.62'}]}]}, {'title': 'ANG 2: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '-35.6', 'spread': '22.91', 'groupId': 'OG000', 'lowerLimit': '22.91'}, {'value': '-4.5', 'spread': '20.05', 'groupId': 'OG001', 'lowerLimit': '20.05'}]}]}, {'title': 'ANG 2: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '-38.9', 'spread': '19.83', 'groupId': 'OG000', 'lowerLimit': '19.83'}, {'value': '7.0', 'spread': '23.25', 'groupId': 'OG001', 'lowerLimit': '23.25'}]}]}, {'title': 'ANG 2: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '-36.7', 'spread': '23.59', 'groupId': 'OG000', 'lowerLimit': '23.59'}, {'value': '-3.6', 'spread': '24.82', 'groupId': 'OG001', 'lowerLimit': '24.82'}]}]}, {'title': 'ANG 2: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '-41.4', 'spread': '21.20', 'groupId': 'OG000', 'lowerLimit': '21.20'}, {'value': '1.0', 'spread': '32.83', 'groupId': 'OG001', 'lowerLimit': '32.83'}]}]}, {'title': 'ANG 2: Cycle 8 Day 1', 'categories': [{'measurements': [{'value': '-40.2', 'spread': '25.33', 'groupId': 'OG000', 'lowerLimit': '25.33'}, {'value': '-6.7', 'spread': '31.26', 'groupId': 'OG001', 'lowerLimit': '31.26'}]}]}, {'title': 'ANG 2: Cycle 9 Day 1', 'categories': [{'measurements': [{'value': '-39.6', 'spread': '14.04', 'groupId': 'OG000', 'lowerLimit': '14.04'}, {'value': '-1.1', 'spread': '29.68', 'groupId': 'OG001', 'lowerLimit': '29.68'}]}]}, {'title': 'ANG 2: Off-Treatment', 'categories': [{'measurements': [{'value': '11.7', 'spread': '99.13', 'groupId': 'OG000', 'lowerLimit': '99.13'}, {'value': '16.8', 'spread': '27.88', 'groupId': 'OG001', 'lowerLimit': '27.88'}]}]}, {'title': 'FGF19: Cycle 1 Day 15', 'categories': [{'measurements': [{'value': '75.0', 'spread': '155.01', 'groupId': 'OG000', 'lowerLimit': '155.01'}, {'value': '1.3', 'spread': '83.65', 'groupId': 'OG001', 'lowerLimit': '83.65'}]}]}, {'title': 'FGF19: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '66.5', 'spread': '134.26', 'groupId': 'OG000', 'lowerLimit': '134.26'}, {'value': '36.6', 'spread': '119.65', 'groupId': 'OG001', 'lowerLimit': '119.65'}]}]}, {'title': 'FGF19: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '86.9', 'spread': '123.85', 'groupId': 'OG000', 'lowerLimit': '123.85'}, {'value': '22.8', 'spread': '70.58', 'groupId': 'OG001', 'lowerLimit': '70.58'}]}]}, {'title': 'FGF19: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '208.1', 'spread': '602.11', 'groupId': 'OG000', 'lowerLimit': '602.11'}, {'value': '46.8', 'spread': '214.14', 'groupId': 'OG001', 'lowerLimit': '214.14'}]}]}, {'title': 'FGF19: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '152.8', 'spread': '228.37', 'groupId': 'OG000', 'lowerLimit': '228.37'}, {'value': '-1.0', 'spread': '40.36', 'groupId': 'OG001', 'lowerLimit': '40.36'}]}]}, {'title': 'FGF19: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '119.8', 'spread': '203.81', 'groupId': 'OG000', 'lowerLimit': '203.81'}, {'value': '26.9', 'spread': '67.13', 'groupId': 'OG001', 'lowerLimit': '67.13'}]}]}, {'title': 'FGF19: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '64.4', 'spread': '101.97', 'groupId': 'OG000', 'lowerLimit': '101.97'}, {'value': '-5.9', 'spread': '57.39', 'groupId': 'OG001', 'lowerLimit': '57.39'}]}]}, {'title': 'FGF19: Cycle 8 Day 1', 'categories': [{'measurements': [{'value': '95.8', 'spread': '135.31', 'groupId': 'OG000', 'lowerLimit': '135.31'}, {'value': '53.9', 'spread': '113.79', 'groupId': 'OG001', 'lowerLimit': '113.79'}]}]}, {'title': 'FGF19: Cycle 9 Day 1', 'categories': [{'measurements': [{'value': '159.3', 'spread': '202.00', 'groupId': 'OG000', 'lowerLimit': '202.00'}, {'value': '56.6', 'spread': '109.46', 'groupId': 'OG001', 'lowerLimit': '109.46'}]}]}, {'title': 'FGF19: Off-Treatment', 'categories': [{'measurements': [{'value': '140.1', 'spread': '270.73', 'groupId': 'OG000', 'lowerLimit': '270.73'}, {'value': '9.0', 'spread': '64.17', 'groupId': 'OG001', 'lowerLimit': '64.17'}]}]}, {'title': 'FGF 21: Cycle 1 Day 15', 'categories': [{'measurements': [{'value': '22.0', 'spread': '75.22', 'groupId': 'OG000', 'lowerLimit': '75.22'}, {'value': '4.0', 'spread': '43.14', 'groupId': 'OG001', 'lowerLimit': '43.14'}]}]}, {'title': 'FGF 21: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '15.7', 'spread': '77.44', 'groupId': 'OG000', 'lowerLimit': '77.44'}, {'value': '18.6', 'spread': '57.18', 'groupId': 'OG001', 'lowerLimit': '57.18'}]}]}, {'title': 'FGF 21: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '38.3', 'spread': '38.3', 'groupId': 'OG000', 'lowerLimit': '38.3'}, {'value': '49.4', 'spread': '76.43', 'groupId': 'OG001', 'lowerLimit': '76.43'}]}]}, {'title': 'FGF 21: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '42.9', 'spread': '145.43', 'groupId': 'OG000', 'lowerLimit': '145.43'}, {'value': '32.8', 'spread': '70.63', 'groupId': 'OG001', 'lowerLimit': '70.63'}]}]}, {'title': 'FGF 21: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '41.0', 'spread': '95.97', 'groupId': 'OG000', 'lowerLimit': '95.97'}, {'value': '31.1', 'spread': '43.15', 'groupId': 'OG001', 'lowerLimit': '43.15'}]}]}, {'title': 'FGF 21: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '52.6', 'spread': '168.22', 'groupId': 'OG000', 'lowerLimit': '168.22'}, {'value': '23.2', 'spread': '40.90', 'groupId': 'OG001', 'lowerLimit': '40.90'}]}]}, {'title': 'FGF 21: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '63.4', 'spread': '128.34', 'groupId': 'OG000', 'lowerLimit': '128.34'}, {'value': '23.7', 'spread': '53.84', 'groupId': 'OG001', 'lowerLimit': '53.84'}]}]}, {'title': 'FGF 21 : Cycle 8 Day1', 'categories': [{'measurements': [{'value': '38.3', 'spread': '115.53', 'groupId': 'OG000', 'lowerLimit': '115.53'}, {'value': '17.0', 'spread': '68.51', 'groupId': 'OG001', 'lowerLimit': '68.51'}]}]}, {'title': 'FGF 21: Cycle 9 Day1', 'categories': [{'measurements': [{'value': '59.1', 'spread': '108.39', 'groupId': 'OG000', 'lowerLimit': '108.39'}, {'value': '68.9', 'spread': '103.55', 'groupId': 'OG001', 'lowerLimit': '103.55'}]}]}, {'title': 'FGF 21: Off-Treatment', 'categories': [{'measurements': [{'value': '141.4', 'spread': '340.51', 'groupId': 'OG000', 'lowerLimit': '340.51'}, {'value': '104.9', 'spread': '183.28', 'groupId': 'OG001', 'lowerLimit': '183.28'}]}]}, {'title': 'FGF 23: Cycle 1 Day15', 'categories': [{'measurements': [{'value': '23.9', 'spread': '49.01', 'groupId': 'OG000', 'lowerLimit': '49.01'}, {'value': '-16.3', 'spread': '36.14', 'groupId': 'OG001', 'lowerLimit': '36.14'}]}]}, {'title': 'FGF 23: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '20.9', 'spread': '56.91', 'groupId': 'OG000', 'lowerLimit': '56.91'}, {'value': '-6.2', 'spread': '48.18', 'groupId': 'OG001', 'lowerLimit': '48.18'}]}]}, {'title': 'FGF 23: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '25.5', 'spread': '45.27', 'groupId': 'OG000', 'lowerLimit': '45.27'}, {'value': '17.3', 'spread': '75.25', 'groupId': 'OG001', 'lowerLimit': '75.25'}]}]}, {'title': 'FGF 23: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '29.5', 'spread': '48.38', 'groupId': 'OG000', 'lowerLimit': '48.38'}, {'value': '14.2', 'spread': '49.29', 'groupId': 'OG001', 'lowerLimit': '49.29'}]}]}, {'title': 'FGF 23: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '29.6', 'spread': '63.69', 'groupId': 'OG000', 'lowerLimit': '63.69'}, {'value': '1.0', 'spread': '47.28', 'groupId': 'OG001', 'lowerLimit': '47.28'}]}]}, {'title': 'FGF 23: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '26.3', 'spread': '54.57', 'groupId': 'OG000', 'lowerLimit': '54.57'}, {'value': '-10.6', 'spread': '46.15', 'groupId': 'OG001', 'lowerLimit': '46.15'}]}]}, {'title': 'FGF 23: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '31.5', 'spread': '57.44', 'groupId': 'OG000', 'lowerLimit': '57.44'}, {'value': '0.7', 'spread': '46.95', 'groupId': 'OG001', 'lowerLimit': '46.95'}]}]}, {'title': 'FGF 23: Cycle 8 Day 1', 'categories': [{'measurements': [{'value': '38.1', 'spread': '67.35', 'groupId': 'OG000', 'lowerLimit': '67.35'}, {'value': '2.8', 'spread': '43.84', 'groupId': 'OG001', 'lowerLimit': '43.84'}]}]}, {'title': 'FGF 23: Cycle 9 Day 1', 'categories': [{'measurements': [{'value': '23.2', 'spread': '62.58', 'groupId': 'OG000', 'lowerLimit': '62.58'}, {'value': '0.5', 'spread': '38.74', 'groupId': 'OG001', 'lowerLimit': '38.74'}]}]}, {'title': 'FGF 23: Off-Treatment', 'categories': [{'measurements': [{'value': '17.8', 'spread': '73.59', 'groupId': 'OG000', 'lowerLimit': '73.59'}, {'value': '14.2', 'spread': '47.11', 'groupId': 'OG001', 'lowerLimit': '47.11'}]}]}, {'title': 'PIVKA-II: Cycle 1 Day 15', 'categories': [{'measurements': [{'value': '80.0', 'spread': '171.41', 'groupId': 'OG000', 'lowerLimit': '171.41'}, {'value': '166.9', 'spread': '256.04', 'groupId': 'OG001', 'lowerLimit': '256.04'}]}]}, {'title': 'PIVKA-II: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '169.7', 'spread': '329.33', 'groupId': 'OG000', 'lowerLimit': '329.33'}, {'value': '243.8', 'spread': '416.82', 'groupId': 'OG001', 'lowerLimit': '416.82'}]}]}, {'title': 'PIVKA-II: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '252.4', 'spread': '611.40', 'groupId': 'OG000', 'lowerLimit': '611.40'}, {'value': '218.7', 'spread': '281.45', 'groupId': 'OG001', 'lowerLimit': '281.45'}]}]}, {'title': 'PIVKA-II: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '371.7', 'spread': '812.45', 'groupId': 'OG000', 'lowerLimit': '812.45'}, {'value': '196.2', 'spread': '348.80', 'groupId': 'OG001', 'lowerLimit': '348.80'}]}]}, {'title': 'PIVKA-II: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '628.2', 'spread': '1752.64', 'groupId': 'OG000', 'lowerLimit': '1752.64'}, {'value': '369.5', 'spread': '766.59', 'groupId': 'OG001', 'lowerLimit': '766.59'}]}]}, {'title': 'PIVKA-II: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '648.7', 'spread': '2746.41', 'groupId': 'OG000', 'lowerLimit': '2746.41'}, {'value': '415.7', 'spread': '554.27', 'groupId': 'OG001', 'lowerLimit': '554.27'}]}]}, {'title': 'PIVKA-II: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '184.8', 'spread': '352.75', 'groupId': 'OG000', 'lowerLimit': '352.75'}, {'value': '703.6', 'spread': '1226.58', 'groupId': 'OG001', 'lowerLimit': '1226.58'}]}]}, {'title': 'PIVKA-II: Cycle 8 Day 1', 'categories': [{'measurements': [{'value': '277.8', 'spread': '481.53', 'groupId': 'OG000', 'lowerLimit': '481.53'}, {'value': '724.0', 'spread': '1257.87', 'groupId': 'OG001', 'lowerLimit': '1257.87'}]}]}, {'title': 'PIVKA-II: Cycle 9 Day 1', 'categories': [{'measurements': [{'value': '318.8', 'spread': '577.21', 'groupId': 'OG000', 'lowerLimit': '577.21'}, {'value': '859.1', 'spread': '1492.93', 'groupId': 'OG001', 'lowerLimit': '1492.93'}]}]}, {'title': 'PIVKA-II: Off-Treatment', 'categories': [{'measurements': [{'value': '809.3', 'spread': '1827.42', 'groupId': 'OG000', 'lowerLimit': '1827.42'}, {'value': '272.5', 'spread': '489.60', 'groupId': 'OG001', 'lowerLimit': '489.60'}]}]}, {'title': 'VEGF: Cycle 1 Day 15', 'categories': [{'measurements': [{'value': '157.5', 'spread': '300.21', 'groupId': 'OG000', 'lowerLimit': '300.21'}, {'value': '97.4', 'spread': '118.43', 'groupId': 'OG001', 'lowerLimit': '118.43'}]}]}, {'title': 'VEGF: Cycle 2 Day 1', 'categories': [{'measurements': [{'value': '128.9', 'spread': '333.85', 'groupId': 'OG000', 'lowerLimit': '333.85'}, {'value': '94.0', 'spread': '180.80', 'groupId': 'OG001', 'lowerLimit': '180.80'}]}]}, {'title': 'VEGF: Cycle 3 Day 1', 'categories': [{'measurements': [{'value': '97.7', 'spread': '162.39', 'groupId': 'OG000', 'lowerLimit': '162.39'}, {'value': '66.0', 'spread': '124.58', 'groupId': 'OG001', 'lowerLimit': '124.58'}]}]}, {'title': 'VEGF: Cycle 4 Day 1', 'categories': [{'measurements': [{'value': '113.4', 'spread': '231.19', 'groupId': 'OG000', 'lowerLimit': '231.19'}, {'value': '76.1', 'spread': '111.20', 'groupId': 'OG001', 'lowerLimit': '111.20'}]}]}, {'title': 'VEGF: Cycle 5 Day 1', 'categories': [{'measurements': [{'value': '132.4', 'spread': '249.59', 'groupId': 'OG000', 'lowerLimit': '249.59'}, {'value': '116.2', 'spread': '215.57', 'groupId': 'OG001', 'lowerLimit': '215.57'}]}]}, {'title': 'VEGF: Cycle 6 Day 1', 'categories': [{'measurements': [{'value': '113.1', 'spread': '219.36', 'groupId': 'OG000', 'lowerLimit': '219.36'}, {'value': '130.9', 'spread': '341.12', 'groupId': 'OG001', 'lowerLimit': '341.12'}]}]}, {'title': 'VEGF: Cycle 7 Day 1', 'categories': [{'measurements': [{'value': '133.1', 'spread': '383.43', 'groupId': 'OG000', 'lowerLimit': '383.43'}, {'value': '96.9', 'spread': '173.77', 'groupId': 'OG001', 'lowerLimit': '173.77'}]}]}, {'title': 'VEGF: Cycle 8 Day 1', 'categories': [{'measurements': [{'value': '148.7', 'spread': '349.58', 'groupId': 'OG000', 'lowerLimit': '349.58'}, {'value': '181.1', 'spread': '399.67', 'groupId': 'OG001', 'lowerLimit': '399.67'}]}]}, {'title': 'VEGF: Cycle 9 Day 1', 'categories': [{'measurements': [{'value': '129.6', 'spread': '215.05', 'groupId': 'OG000', 'lowerLimit': '215.05'}, {'value': '135.6', 'spread': '267.61', 'groupId': 'OG001', 'lowerLimit': '267.61'}]}]}, {'title': 'VEGF: Off-Treatment', 'categories': [{'measurements': [{'value': '127.1', 'spread': '266.64', 'groupId': 'OG000', 'lowerLimit': '266.64'}, {'value': '147.8', 'spread': '304.31', 'groupId': 'OG001', 'lowerLimit': '304.31'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The pharmacodynamics (PD) analysis set included all participants who received at least 1 dose of study drug and had evaluable PD data. Here "n" was participants who were evaluable for the outcome measure at given time points.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Lenvatinib', 'description': "Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'FG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '478'}, {'groupId': 'FG001', 'numSubjects': '476'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '476'}, {'groupId': 'FG001', 'numSubjects': '475'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '478'}, {'groupId': 'FG001', 'numSubjects': '476'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '415'}, {'groupId': 'FG001', 'numSubjects': '402'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '12'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'Sponsor Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '41'}, {'groupId': 'FG001', 'numSubjects': '52'}]}]}], 'recruitmentDetails': 'Participants took part in the study at 154 investigative sites in Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Malaysia, Philippines, Poland, Russia, Singapore, Spain, Taiwan, Thailand, United Kingdom, and the United States from 1 March 2013 to 10 March 2021.', 'preAssignmentDetails': 'A total of 1,492 participants were screened, 954 participants were enrolled and randomized, out of which 951 participants were treated in the study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '478', 'groupId': 'BG000'}, {'value': '476', 'groupId': 'BG001'}, {'value': '954', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Lenvatinib', 'description': "Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent."}, {'id': 'BG001', 'title': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '61.3', 'spread': '11.69', 'groupId': 'BG000'}, {'value': '61.2', 'spread': '12.01', 'groupId': 'BG001'}, {'value': '61.3', 'spread': '11.84', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '73', 'groupId': 'BG000'}, {'value': '75', 'groupId': 'BG001'}, {'value': '148', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '405', 'groupId': 'BG000'}, {'value': '401', 'groupId': 'BG001'}, {'value': '806', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '472', 'groupId': 'BG000'}, {'value': '465', 'groupId': 'BG001'}, {'value': '937', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '334', 'groupId': 'BG000'}, {'value': '326', 'groupId': 'BG001'}, {'value': '660', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '135', 'groupId': 'BG000'}, {'value': '141', 'groupId': 'BG001'}, {'value': '276', 'groupId': 'BG002'}]}, {'title': 'Other', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The full analysis set (FAS) included all participants who were randomized.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 954}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-03-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-03', 'dispFirstSubmitDate': '2018-01-18', 'completionDateStruct': {'date': '2021-03-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-03-08', 'studyFirstSubmitDate': '2013-01-02', 'dispFirstSubmitQcDate': '2018-01-19', 'resultsFirstSubmitDate': '2018-08-27', 'studyFirstSubmitQcDate': '2013-01-03', 'dispFirstPostDateStruct': {'date': '2018-01-25', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2022-04-05', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-08-27', 'studyFirstPostDateStruct': {'date': '2013-01-04', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-09-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-11-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Disease Control Rate (DCR)', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \\>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Clinical Benefit Rate (CBR)', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \\>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Percent Change From Baseline in Serum Biomarker', 'timeFrame': 'Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.'}], 'primaryOutcomes': [{'measure': 'Overall Survival (OS)', 'timeFrame': 'From date of randomization until date of death from any cause (approximately up to 3.8 years)', 'description': 'OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.'}], 'secondaryOutcomes': [{'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Time to Progression (TTP)', 'timeFrame': 'The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)', 'description': 'TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)', 'timeFrame': 'Baseline up to Off-Treatment Visit (approximately up to 3.8 years)', 'description': 'The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}, {'measure': 'Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib', 'timeFrame': 'Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)', 'description': 'AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Hepatocellular Carcinoma', 'Neoplasms', 'Cancer'], 'conditions': ['Hepatocellular Carcinoma (HCC)']}, 'referencesModule': {'references': [{'pmid': '38261521', 'type': 'DERIVED', 'citation': 'Piscaglia F, Ikeda K, Cheng AL, Kudo M, Ikeda M, Breder V, Ryoo BY, Mody K, Ren M, Ramji Z, Sung MW. Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study. Cancer. 2024 Apr 15;130(8):1281-1291. doi: 10.1002/cncr.35185. Epub 2024 Jan 23.'}, {'pmid': '36341767', 'type': 'DERIVED', 'citation': 'Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, Lopez CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20.'}, {'pmid': '36051472', 'type': 'DERIVED', 'citation': 'Huynh J, Cho MT, Kim EJ, Ren M, Ramji Z, Vogel A. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol. 2022 Aug 24;14:17588359221116608. doi: 10.1177/17588359221116608. eCollection 2022.'}, {'pmid': '34087115', 'type': 'DERIVED', 'citation': 'Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.'}, {'pmid': '33948712', 'type': 'DERIVED', 'citation': 'Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol. 2021 Jun;56(6):570-580. doi: 10.1007/s00535-021-01785-0. Epub 2021 May 4.'}, {'pmid': '32265508', 'type': 'DERIVED', 'citation': 'Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020 Jun;122(12):1754-1759. doi: 10.1038/s41416-020-0817-7. Epub 2020 Apr 8.'}, {'pmid': '31720835', 'type': 'DERIVED', 'citation': 'Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.'}, {'pmid': '31249394', 'type': 'DERIVED', 'citation': 'Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28.'}, {'pmid': '29433850', 'type': 'DERIVED', 'citation': 'Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.'}]}, 'descriptionModule': {'briefSummary': 'E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "1. Participants must have confirmed diagnosis of unresectable HCC with any of the following criteria:\n\n * Histologically or cytologically confirmed diagnosis of HCC.\n * Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or with chronic hepatitis B or C infection criteria\n2. At least one measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) meeting the following criteria:\n\n • Hepatic lesion\n 1. The lesion can be accurately measured in at least one dimension as \\>=1.0 centimeter (cm) (viable tumor for typical; and longest diameter for atypical), and\n 2. The lesion is suitable for repeat measurement.\n\n • Nonhepatic lesion\n 3. Lymph node (LN) lesion that measures at least one dimension as \\>=1.5 cm in the short axis, except for porta hepatis LN that measures \\>=2.0 cm in the short axis.\n 4. Non-nodal lesion that measures \\>=1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.\n3. Participants categorized to stage B (not applicable for transarterial chemoembolization \\[TACE\\]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system.\n4. Adequate bone marrow function, defined as:\n\n * Absolute neutrophil count (ANC) \\>=1.5 X 10\\^9 per liter (/L)\n * Hemoglobin (Hb) \\>=8.5 gram per deciliter (g/dL)\n * Platelet count \\>=75 X 10\\^9/L.\n5. Adequate liver function, defined as:\n\n * Albumin \\>=2.8 g/dL\n * Bilirubin less than or equal to (\\<=) 3.0 mg/dL\n * Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) \\<=5 X the upper limit of normal (ULN).\n6. Adequate blood coagulation function, defined as international normalized ratio (INR) \\<=2.3.\n7. Adequate renal function defined as creatinine clearance greater than (\\>) 40 milliliter per minute (mL/min) calculated per the Cockcroft and Gault formula.\n8. Adequate pancreatic function, defined as amylase and lipase \\<=1.5 X ULN.\n9. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP \\<=150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive therapy within 1 week prior to the Cycle1/Day1.\n10. Child-Pugh score A.\n11. Eastern Cooperative Oncology Group (ECOG)- performance status (PS) 0 or 1.\n12. Males or females aged at least 18 years (or any age \\>18 years as determined by country legislation) at the time of informed consent.\n13. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin \\[B-hCG\\] test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of BhCG).\n\n A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.\n14. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least 1 month before dosing).\n15. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double barrier method \\[such as condom plus diaphragm with spermicide\\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.\n16. Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.\n17. Provide written informed consent.\n18. Willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria\n\n1. Imaging findings for HCC corresponding to any of the following:\n\n * HCC with \\>=50 percent liver occupation\n * Clear invasion into the bile duct\n * Portal vein invasion at the main portal branch (Vp4).\n2. Participants who have received any systemic chemotherapy, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agents, including lenvatinib, for advanced/unresectable HCC. Note: Participants who have received local hepatic injection chemotherapy are eligible.\n3. Participants who have received any anticancer therapy (including surgery, percutaneous ethanol injection, radio frequency ablation, transarterial \\[chemo\\] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production, eg, granulocyte colony-stimulating factor \\[G-CSF\\]) within 28 days prior to randomization.\n4. Participants who have not recovered from toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as \\< Grade 2 severity per Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).\n5. Significant cardiovascular impairment: history of congestive heart failure \\> New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.\n6. Prolongation of corrected QT interval (QTc) interval to \\>480 millisecond (ms)\n7. Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator.\n8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, eg, warfarin or similar agents. Treatment with low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted. Antiplatelet agents are prohibited throughout the study.\n9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization.\n10. Gastric or esophageal varices that require interventional treatment within 28 days prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective beta-blocker) is permitted.\n11. Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 36 months.\n12. Participants whose only target lesion(s) is in bone will be excluded.\n13. Meningeal carcinomatosis.\n14. Any history of or current brain or subdural metastases.\n15. Participants having \\>1+ proteinuria on urine dipstick testing will undergo a 24-hour urine collection for quantitative assessment of proteinuria. Participants with a urine protein \\>=1g/24 hours will be ineligible.\n16. Surgical arterial-portal venous shunt or arterial-venous shunt.\n17. Any medical or other condition that in the opinion of the investigator would preclude the participant's participation in a clinical study.\n18. Known intolerance to lenvatinib or sorafenib (or any of the excipients).\n19. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus).\n20. Any history of drug or alcohol dependency or abuse within the prior 6 months.\n21. Any participant who cannot be evaluated by either triphasic liver computed tomography (CT) or triphasic liver Magnetic resonance imaging (MRI) because of allergy or other contraindication to both CT and MRI contrast agents.\n22. Major surgery within 3 weeks prior to randomization or scheduled for surgery during the study.\n23. Participants has had a liver transplant."}, 'identificationModule': {'nctId': 'NCT01761266', 'briefTitle': 'A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eisai Inc.'}, 'officialTitle': 'A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma', 'orgStudyIdInfo': {'id': 'E7080-G000-304'}, 'secondaryIdInfos': [{'id': '2012-002992-33', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Lenvatinib', 'description': "Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.", 'interventionNames': ['Drug: Lenvatinib']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Sorafenib', 'description': 'Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.', 'interventionNames': ['Drug: Sorafenib']}], 'interventions': [{'name': 'Lenvatinib', 'type': 'DRUG', 'otherNames': ['E7080, Lenvima'], 'description': '12 mg (or 8 mg) once daily (QD) oral dosing.', 'armGroupLabels': ['Lenvatinib']}, {'name': 'Sorafenib', 'type': 'DRUG', 'description': '400 mg twice daily (BID) oral dosing.', 'armGroupLabels': ['Sorafenib']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'city': 'Duluth', 'state': 'Georgia', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.00288, 'lon': -84.14464}}, {'city': 'Lawrenceville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.95621, 'lon': -83.98796}}, {'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'city': 'East Orange', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.76732, 'lon': -74.20487}}, {'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'city': 'Lake Success', 'state': 'New York', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.77066, 'lon': -73.71763}}, {'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'city': 'Lubbock', 'state': 'Texas', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.57786, 'lon': -101.85517}}, {'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Facility # 1', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'city': 'Camperdown', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -33.88965, 'lon': 151.17642}}, {'city': 'Wentworthville', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -33.80652, 'lon': 150.96785}}, {'city': 'Woolloongabba', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'city': 'Fitzroy', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -37.79839, 'lon': 144.97833}}, {'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Facility # 2', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Facility # 1', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'city': 'Brussels', 'country': 'Belgium', 'facility': 'Facility # 1', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Edegem', 'country': 'Belgium', 'facility': 'Facility # 1', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'city': 'Liège', 'country': 'Belgium', 'facility': 'Facility # 1', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Facility # 1', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Facility # 2', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Facility # 3', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Chongqing', 'state': 'Chongqing Municipality', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'city': 'Fuzhou', 'state': 'Fujian', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'city': 'Fuzhou', 'state': 'Fujian', 'country': 'China', 'facility': 'Facility # 2', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Harbin', 'state': 'Heilongjiang', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'city': 'Changsha', 'state': 'Hunan', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'city': 'Nanjing', 'state': 'Jiangsu', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'city': 'Suzhou', 'state': 'Jiangsu', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 31.30408, 'lon': 120.59538}}, {'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'city': 'Dalian', 'state': 'Liaoning', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Facility # 3', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'city': 'Xi’an', 'state': 'Shanxi', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.99785, 'lon': 113.52486}}, {'city': 'Xi’an', 'state': 'Shanxi', 'country': 'China', 'facility': 'Facility # 2', 'geoPoint': {'lat': 35.99785, 'lon': 113.52486}}, {'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'city': 'Tianjin', 'state': 'Zhejiang', 'country': 'China', 'facility': 'Facility # 1', 'geoPoint': {'lat': 30.73454, 'lon': 119.52652}}, {'city': 'Nice', 'state': 'Alpes Maritimes', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'city': 'Pessac', 'state': 'Gironde', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'city': 'Toulouse', 'state': 'Haute Garonne', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'city': 'Montpellier', 'state': 'Herault', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'city': 'Rennes', 'state': 'Ille Et Vilaine', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'city': 'Vandœuvre-lès-Nancy', 'state': 'Meurthe Et Moselle', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'city': 'Amiens', 'state': 'Somme', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 49.9, 'lon': 2.3}}, {'city': 'Créteil', 'state': 'Val De Marne', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'city': 'Bordeaux', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Lille', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Lyon', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '59037', 'city': 'Nord', 'country': 'France', 'facility': 'Facility # 1'}, {'zip': '75013', 'city': 'Paris', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75020', 'city': 'Paris', 'country': 'France', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Rhone', 'country': 'France', 'facility': 'Facility # 1'}, {'city': 'Heidelberg', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'city': 'Tübingen', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'city': 'Marburg', 'state': 'Hesse', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'city': 'Hanover', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'city': 'Cologne', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'city': 'Essen', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'city': 'Mainz', 'state': 'Rhineland-Palatinate', 'country': 'Germany', 'facility': 'Facility # 1', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Facility # 1', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Facility # 2', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Facility # 3', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'Kowloon', 'country': 'Hong Kong', 'facility': 'Facility # 1', 'geoPoint': {'lat': 22.31667, 'lon': 114.18333}}, {'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Facility # 1', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'city': 'Torrette', 'state': 'Ancona', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.53485, 'lon': 15.01974}}, {'city': 'Bari', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'city': 'Benevento', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 41.1307, 'lon': 14.77816}}, {'city': 'Bologna', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'city': 'Napoli', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Napoli', 'country': 'Italy', 'facility': 'Facility # 2', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Palermo', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'city': 'Roma', 'country': 'Italy', 'facility': 'Facility # 1', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'city': 'Kashiwa', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'city': 'Matsuyama', 'state': 'Ehime', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.83916, 'lon': 132.76574}}, {'city': 'Kurume', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.31667, 'lon': 130.51667}}, {'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Nishinomiya', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.71562, 'lon': 135.33199}}, {'city': 'Kanazawa', 'state': 'Ishikawa-ken', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 36.6, 'lon': 136.61667}}, {'city': 'Kawasaki', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.52056, 'lon': 139.71722}}, {'city': 'Yokohama', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'city': 'Tsu', 'state': 'Mie-ken', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.73333, 'lon': 136.51667}}, {'city': 'Ōmura', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 32.92139, 'lon': 129.95389}}, {'city': 'Ōsaka-sayama', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.49524, 'lon': 135.55069}}, {'city': 'Bunkyo-Ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Facility # 1'}, {'city': 'Chuo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Facility # 1'}, {'city': 'Koto-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Facility # 1'}, {'city': 'Minato-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Facility # 1'}, {'city': 'Musashino', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.70611, 'lon': 139.55944}}, {'city': 'Shimonoseki', 'state': 'Yamaguchi', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.95548, 'lon': 130.93713}}, {'city': 'Fukuoka', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'city': 'Hiroshima', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'city': 'Okayama', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 34.65, 'lon': 133.93333}}, {'city': 'Osaka', 'country': 'Japan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Saga', 'country': 'Japan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 33.23333, 'lon': 130.3}}, {'city': 'Saga', 'country': 'Japan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 33.23333, 'lon': 130.3}}, {'city': 'Kuantan', 'state': 'Pahang', 'country': 'Malaysia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 3.8077, 'lon': 103.326}}, {'city': 'George Town', 'state': 'Pulau Pinang', 'country': 'Malaysia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 5.41123, 'lon': 100.33543}}, {'city': 'Miri', 'state': 'Sarawak', 'country': 'Malaysia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 4.39928, 'lon': 113.99163}}, {'city': 'Batu Caves', 'state': 'Selangor', 'country': 'Malaysia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 3.238, 'lon': 101.682}}, {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'Cebu City', 'country': 'Philippines', 'facility': 'Facility # 1', 'geoPoint': {'lat': 10.31672, 'lon': 123.89071}}, {'city': 'Cebu City', 'country': 'Philippines', 'facility': 'Facility # 2', 'geoPoint': {'lat': 10.31672, 'lon': 123.89071}}, {'city': 'Davao City', 'country': 'Philippines', 'facility': 'Facility # 1', 'geoPoint': {'lat': 7.07306, 'lon': 125.61278}}, {'city': 'Quezon City', 'country': 'Philippines', 'facility': 'Facility # 1', 'geoPoint': {'lat': 14.6488, 'lon': 121.0509}}, {'city': 'Quezon City', 'country': 'Philippines', 'facility': 'Facility # 2', 'geoPoint': {'lat': 14.6488, 'lon': 121.0509}}, {'city': 'Gdansk', 'country': 'Poland', 'facility': 'Facility # 1', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'city': 'Warsaw', 'country': 'Poland', 'facility': 'Facility # 1', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Facility # 1', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'city': 'Arkhangelsk', 'country': 'Russia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 64.5461, 'lon': 40.55183}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'Facility # 2', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Facility # 3', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Facility # 4', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Ufa', 'country': 'Russia', 'facility': 'Facility # 1', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Facility # 1', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Facility # 2', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Facility # 3', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Facility # 4', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Goyang-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}}, {'city': 'Seongnam-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'city': 'Seongnam-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Facility # 2', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'city': 'Suwon', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'city': 'Daegu', 'state': 'Gyeongsangbuk-do', 'country': 'South Korea', 'facility': 'Facility # 1'}, {'city': 'Hwasun', 'state': 'Jeollanam-do', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.06125, 'lon': 126.98746}}, {'city': 'Busan', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'city': 'Busan', 'country': 'South Korea', 'facility': 'Facility # 2', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'city': 'Busan', 'country': 'South Korea', 'facility': 'Facility # 3', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'city': 'Incheon', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 1', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 2', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 3', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 4', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 5', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 6', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 7', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Facility # 8', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Facility # 1', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'city': 'Santander', 'state': 'Cantabria', 'country': 'Spain', 'facility': 'Facility # 1', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}, {'city': 'Badajoz', 'country': 'Spain', 'facility': 'Facility # 1', 'geoPoint': {'lat': 38.87789, 'lon': -6.97061}}, {'city': 'Girona', 'country': 'Spain', 'facility': 'Facility # 1', 'geoPoint': {'lat': 41.98311, 'lon': 2.82493}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Facility # 1', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Facility # 2', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Facility # 3', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Facility # 4', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Facility # 2', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Facility # 3', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Facility # 4', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Facility # 5', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Taoyuan', 'country': 'Taiwan', 'facility': 'Facility # 1', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}, {'city': 'Bangkoknoi', 'state': 'Bangkok', 'country': 'Thailand', 'facility': 'Facility # 1'}, {'city': 'Pathum Wan', 'state': 'Bangkok', 'country': 'Thailand', 'facility': 'Facility # 1', 'geoPoint': {'lat': 13.73649, 'lon': 100.5239}}, {'city': 'Ratchathewi', 'state': 'Bangkok', 'country': 'Thailand', 'facility': 'Facility # 1', 'geoPoint': {'lat': 13.759, 'lon': 100.53358}}, {'city': 'Muang', 'state': 'Changwat Chiang Rai', 'country': 'Thailand', 'facility': 'Facility # 1'}, {'city': 'Muang', 'state': 'Chiang Mai', 'country': 'Thailand', 'facility': 'Facility # 1'}, {'zip': 'W12 OHS', 'city': 'London', 'state': 'Greater London', 'country': 'United Kingdom', 'facility': 'Facility # 2', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'state': 'Greater London', 'country': 'United Kingdom', 'facility': 'Facility # 1', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'state': 'Greater London', 'country': 'United Kingdom', 'facility': 'Facility # 3', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Manchester', 'state': 'Greater Manchester', 'country': 'United Kingdom', 'facility': 'Facility # 1', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'city': 'Liverpool', 'state': 'Merseyside', 'country': 'United Kingdom', 'facility': 'Facility # 1', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'city': 'Glasgow', 'state': 'Strathclyde', 'country': 'United Kingdom', 'facility': 'Facility # 1', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'city': 'Birmingham', 'state': 'West Midlands', 'country': 'United Kingdom', 'facility': 'Facility # 1', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eisai Limited', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}